Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

- Gleevec found to dramatically reduce the risk of cancer returning after surgery for Kit-positive gastrointestinal stromal tumors (GIST)

EAST HANOVER, N.J., April 12, 2007 /PRNewswire/ -- Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

The interim analysis showed no recurrence of cancer in approximately 97% of patients given Gleevec for a year after surgery to remove tumors, compared to approximately 83% of those who underwent surgery but received a placebo. The investigators made these results public because the study had met its primary endpoint in terms of rate of recurrence-free survival.

The study involving more than 600 patients was sponsored by the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH). It was conducted at multiple cancer centers in the US and Canada, and was led by the of Surgeons Oncology Group. Novartis supplied Gleevec for use in the study, and also provided partial funding under a Cooperative Research and Development Agreement with NCI to support the clinical development of Gleevec.

Gleevec has already been confirmed as an effective therapy in its approved use for patients with advanced metastatic or unresectable (inoperable) Kit- positive GIST. In a statement issued today by the NIH, the new findings were heralded as excellent news, with major implications for patients with primary disease.

"With these new data, we see that Gleevec may help patients with early GIST," said Diane Young, MD, Head of Global Medical Affairs at Novartis Oncology. "We will now work with the investig
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/27/2015)... 2015 Even the Score today announced the ... as scientific co-chair for the coalition. Dr. Larkin will ... an expert voice in the important conversation regarding the ... with Hypoactive Sexual Desire Disorder (HSDD), women,s most common ... honored to join Even the Score as its co-chair ...
(Date:7/27/2015)... 20, 2015 Research and Markets ( http://www.researchandmarkets.com/research/t63pbj/medical_device ... Device Regulation in Asia/Pacific Markets Seminar" conference to ... Medical Device market is well established, the next growth ... China , together with other countries in this ... of implementing, their own medical device regulations. This seminar ...
(Date:7/27/2015)... 27, 2015 Research and Markets ... of the "Wound Care -Traditonal, Advanced ... Analysis And Forecasts" report to their ... evaluation of the global Wound Care products ... product offerings, competitive shares, financial performance, technology ...
Breaking Medicine Technology:Dr. Lisa Larkin Joins the Even the Score Coalition as Scientific Co-Chair 2Dr. Lisa Larkin Joins the Even the Score Coalition as Scientific Co-Chair 3Medical Device Regulation in Asia/Pacific Markets Seminar: London, UK - 21st, 22nd of September 2015 2Global Wound Care Markets 2015-2020 - Traditonal, Advanced And Regenerative: Competitors And Opportunities 2
... Biopharmaceuticals, Inc. (NASDAQ: KERX ), a biopharmaceutical ... medically important pharmaceutical products for the treatment of cancer ... will be held on Monday, August 8, 2011 at ... quarter ended June 30, 2011 and a business outlook ...
... and SYDNEY, Aug. 4, 2011 HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that ... announced revenues of $20.4 million for the second quarter ... increase from $9.8 million in revenues for the same ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results 2HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010 2HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010 3HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010 4HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010 5HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010 6
(Date:7/28/2015)... ... July 28, 2015 , ... Scientel is thrilled to announce that ... at the McHenry Convention Center in San Jose, Ca. Scientel will be participating ... presentation on Multi-Modeling and the industry’s first polymorphic database will address the critical need ...
(Date:7/27/2015)... (PRWEB) , ... July 28, 2015 , ... Dr. ... announced that his practice has teamed up with Realief Neuropathy Centers in order to ... shown to reverse the signs and symptoms of peripheral neuropathy. , Peripheral neuropathy is ...
(Date:7/27/2015)... , ... July 27, 2015 , ... ... diabetes, are associated with smaller regional brain volumes that may be early indicators ... journal Radiology. , “We already know that vascular risk factors damage the brain ...
(Date:7/27/2015)... ... July 27, 2015 , ... Interactive health ... management. Earlier this year Wound Care Advantage beta launched Luvo University, ... wound centers. Customized learning paths allow for clinicians, physicians, hyperbaric technicians and ...
(Date:7/27/2015)... ... , ... On July 14, 2015, Harper’s Bazaar Magazine in an article titled ... such as stretch marks , fine lines , and acne scars ... listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is pointed out ...
Breaking Medicine News(10 mins):Health News:Scientel Selected to Present at 2015 NoSQLNow! Conference, San Jose August 18-20 2Health News:Scientel Selected to Present at 2015 NoSQLNow! Conference, San Jose August 18-20 3Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 3Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 3Health News:The Latest Treatment Options for Seven Common Skin Issues 2
... NEW YORK, NY -- APRIL 13, 2010 ... clinical research updates to technologies and practices in ... The important role of interventional ... with the announcement that former President Clinton received ...
... ... newly expanded and re-launched ProbioticSmart.com website. Why? Consumers say an expanded selection ... stomach". , ... April 13, 2010 -- Probiotics are quickly being recognized as a great way to ...
... the brain tumor can often be removed surgically, in virtually ... that sporadic, infiltrative tumor cells will remain in the brain ... Bonn have now subjected these ,forgotten, cells to closer scrutiny ... to show that many of the fundamental properties of these ...
... ... performance management data to be captured on iPhones and easily uploaded into management ... ... the leading provider of comprehensive performance management software and services, today ...
... ... promotes its proprietary, all-natural formulations as evidence-based alternatives for the primary care physician, ... force expansion. , ... Whitehouse Station, NJ/Las Vegas, NV (PRWEB) April 14, 2010 -- PreEmptive ...
... , TORONTO New research finds any beneficial effect of drinking ... smoking, according to research that will be presented as part of ... Annual Meeting in Toronto, April 10 17, 2010. ... people in the United Kingdom who were between the ages of ...
Cached Medicine News:Health News:TCT 2010 to have significant impact on interventional cardiology practices and patient care 2Health News:ProbioticSmart.com Re-Launches Newly Expanded Online Store for Human, Pet, and Livestock Health Products and Supplements 2Health News:Brain cancer: Study focuses on forgotten cells 2Health News:ActiveStrategy iRound™ is Launched to Enable Seamless Capture of Field-Level Performance Management Data 2Health News:ActiveStrategy iRound™ is Launched to Enable Seamless Capture of Field-Level Performance Management Data 3Health News:Pilot Testing Phase Ends; Expansion Of Sales Force Begins 2Health News:Pilot Testing Phase Ends; Expansion Of Sales Force Begins 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: